Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 1, 2012, Pages 71-78

  Husken A C ^a   Tsianakas, A ^a   Hensen, P ^b   Nashan, D ^c   Loquai, C ^d   Beissert, S ^a   Luger, T A ^a   Sunderkotter C ^a   Schiller, M ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; METHOXSALEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PSORALEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENERALIZED URTICARIA; HEPATITIS C; HUMAN; LIVER TOXICITY; MALE; MELANOSIS; MYALGIA; NAIL MELANOSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUVA; REMISSION; RETROSPECTIVE STUDY; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN SWELLING; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; FICUSIN; HUMANS; INTERFERON-ALPHA; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; POLYETHYLENE GLYCOLS; PUVA THERAPY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 83755186054     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04011.x     Document Type: Article

References (53)

1. Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007; 43: 2321-2329. (Pubitemid 350001246)
2. Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
3. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581. (Pubitemid 28525182)
4. Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005; 75: 136-145. (Pubitemid 41008284)
5. Rajan G, Seifert B, Prümmer O, Joller-Jemelka H, Burg G, Dummer R,. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon-alpha2a combined with acetretin or PUVA. Arch Derm Res 1996; 288: 543-548. (Pubitemid 26280705)
6. Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13: 257-263.
7. Roenigk H, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95: 198S-205S.
8. Stadler R, Otte HG,. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy. Recent Results Cancer Res 1995; 139: 391-401.
9. Stadler R, Assaf C, Klemke CD, et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 2008; 6 (Suppl. 1): S25-S31.
10. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006; 42: 1014-1030.
11. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785. (Pubitemid 40656118)
12. Foster GR,. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-830. (Pubitemid 39424889)
13. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
14. Ascione A, Luca MD, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin is more effective than peginterferon alpha-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-122.
15. Rumi M, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-115.
16. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27: 2916-2923.
17. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002; 20: 3841-3849.
18. Feldman DR, Kondagunta GV, Schwartz L, et al. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2008; 6: 25-30. (Pubitemid 351656240)
19. Kudo M,. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008; 75 (Suppl. 1): 30-41, Epub, 2008 Dec 17: 30-41.
20. Motzer RJ, Rakhit A, Thompson J, et al. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002; 13: 1799-1805. (Pubitemid 35439461)
21. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
22. Ueshima K, Kudo M, Nagai T, et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology 2008; 75 (Suppl. 1): 106-113, Epub, 2008 Dec 17: 106-113.
23. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126. (Pubitemid 351952257)
24. Eggermont AM, Bouwhuis MG, Kruit WH, et al. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol 2010; 65: 671-677.
25. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283.
26. Loquai C, Nashan D, Hensen P, et al. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. Eur J Dermatol 2008; 18: 29-35. (Pubitemid 351158169)
27. Fujimura T, Okuyama R, Hashimoto A, et al. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon. Acta Derm Venereol 2006; 86: 161-162. (Pubitemid 44020187)
28. Fujimura T, Okuyama R, Watabe A, et al. Interferon-α is effective for CD4+, CCR4- mycosis fungoides. Int J Dermatol 2007; 46: 435-438.
29. Lundin J, Osterborg A,. Therapy for mycosis fungoides. Curr Treat Options Oncol 2004; 5: 203-214. (Pubitemid 39359621)
30. Huber MA, Staib G, Pehamberger H, et al. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006; 7: 155-169. (Pubitemid 43845340)
31. Dummer R,. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006; 33: S33-S36.
32. Tsubota A, Arase Y, Someya T, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 27-34. (Pubitemid 39578786)
33. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110: 2012-2018. (Pubitemid 350036861)
34. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
35. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403. (Pubitemid 32702353)
36. Bex A, Mallo H, Kerst M, et al. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54: 713-719. (Pubitemid 40884168)
37. Clark JI, Mehrabi J, Sosman JA, et al. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. J Immunother 2007; 30: 839-846. (Pubitemid 350295363)
38. George S, Hutson TE, Mekhail T, et al. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2008; 62: 347-354. (Pubitemid 351692077)
39. Hasan F, Al-Khaldi J, Asker H, et al. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004; 9: 499-503. (Pubitemid 39150206)
40. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-1737. (Pubitemid 39237501)
41. Bukowski RM, Tendler C, Cutler D, et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95: 389-396. (Pubitemid 34787605)
42. Bukowski RM,. Pegylated interferon alfa-2b as treatment of patients with solid tumors. Curr Oncol Rep 2003; 5: 87-88.
43. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371. (Pubitemid 27276581)
44. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005; 141: 305-311. (Pubitemid 40365446)
45. Herrmann JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995; 33: 234-242.
46. Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999; 140: 427-431. (Pubitemid 29182872)
47. Islam M, Frye RF, Richards TJ, et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8: 2480-2487. (Pubitemid 34856329)
48. Wong SF, Jakowatz JG, Taheri R,. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. Clin Ther 2005; 27: 1942-1948. (Pubitemid 43293216)
49. Van Gool AR, Kruit WH, Engels FK, et al. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003; 25: 11-20. (Pubitemid 36313885)
50. Fluck M, Kamanabrou D, Lippold A, et al. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Cancer Biother Radiopharm 2005; 20: 280-289. (Pubitemid 41003832)
51. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283.
52. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
53. Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8: 2139-2157. (Pubitemid 35203229)